School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
Br J Cancer. 2013 Aug 20;109(4):1056-62. doi: 10.1038/bjc.2013.336. Epub 2013 Aug 6.
Tumour heterogeneity is documented for many characters, including the production of growth factors, one of the hallmarks of cancer. What maintains heterogeneity remains an open question that has implications for diagnosis and treatment, as drugs that target growth factors are susceptible to the evolution of resistance.
I use evolutionary game theory to model collective interactions between cancer cells, to analyse the dynamics of the production of growth factors and the effect of therapies that reduce their amount.
Five types of dynamics are possible, including the coexistence of producer and non-producer cells, depending on the production cost of the growth factor, on its diffusion range and on the degree of synergy of the benefit it confers to the cells. Perturbations of the equilibrium mimicking therapies that target growth factors are effective in reducing the amount of growth factor in the long term only if the reduction is extremely efficient and immediate.
Collective interactions within the tumour can maintain heterogeneity for the production of growth factors and explain why therapies like anti-angiogenic drugs and RNA interference that reduce the amount of available growth factors are effective in the short term but often lead to relapse. Alternative strategies for evolutionarily stable treatments are discussed.
肿瘤异质性在许多特征中都有记录,包括生长因子的产生,这是癌症的标志之一。维持异质性仍然是一个悬而未决的问题,这对诊断和治疗有影响,因为针对生长因子的药物容易产生耐药性。
我使用进化博弈论来模拟癌细胞之间的集体相互作用,分析生长因子产生的动力学以及减少其数量的治疗方法的效果。
根据生长因子的生产成本、扩散范围以及它赋予细胞的协同效益程度,有五种可能的动力学类型,包括生产者和非生产者细胞的共存。模拟针对生长因子的治疗方法的平衡扰动在长期内仅在减少非常有效且立即时才有效减少生长因子的数量。
肿瘤内的集体相互作用可以维持生长因子产生的异质性,并解释为什么像抗血管生成药物和 RNA 干扰等减少可用生长因子数量的治疗方法在短期内有效,但往往会导致复发。讨论了用于进化稳定治疗的替代策略。